ATE451364T1 - Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate - Google Patents

Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate

Info

Publication number: ATE451364T1
Authority: AT; Austria
Prior art keywords: dopamine; modulators; receptor; derivatives suitable; derivatives
Prior art date: 2004-02-23

Application number

AT05707610T

Other languages

English (en)

Inventor

Luca Arista

Giorgio Bonanomi

Anna Maria Capelli

Federica Damiani

Fabio Romano Di

Gabriella Gentile

Dieter Hamprecht

Fabrizio Micheli

Luca Tarsi

Giovanna Tedesco

Silvia Terreni

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-23

Filing date

2005-02-21

Publication date

2009-12-15

2004-02-23 Priority claimed from GB0403990A external-priority patent/GB0403990D0/en

2004-02-24 Priority claimed from GB0404083A external-priority patent/GB0404083D0/en

2004-07-30 Priority claimed from GB0417120A external-priority patent/GB0417120D0/en

2005-02-21 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2009-12-15 Application granted granted Critical

2009-12-15 Publication of ATE451364T1 publication Critical patent/ATE451364T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Nutrition Science (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT05707610T 2004-02-23 2005-02-21 Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate ATE451364T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0403990A GB0403990D0 (en)	2004-02-23	2004-02-23	Compounds
GB0404083A GB0404083D0 (en)	2004-02-24	2004-02-24	Compounds
GB0417120A GB0417120D0 (en)	2004-07-30	2004-07-30	Compounds
PCT/EP2005/001940 WO2005080382A1 (en)	2004-02-23	2005-02-21	Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors

Publications (1)

Publication Number	Publication Date
ATE451364T1 true ATE451364T1 (de)	2009-12-15

Family

ID=34890800

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
AT08169935T ATE542816T1 (de)	2004-02-23	2005-02-21	Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors
AT05707610T ATE451364T1 (de)	2004-02-23	2005-02-21	Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
AT08169934T ATE520686T1 (de)	2004-02-23	2005-02-21	Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT08169935T ATE542816T1 (de)	2004-02-23	2005-02-21	Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT08169934T ATE520686T1 (de)	2004-02-23	2005-02-21	Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors

Country Status (26)

Country	Link
US (3)	US7855298B2 (de)
EP (3)	EP2060570B1 (de)
JP (1)	JP4960217B2 (de)
KR (1)	KR101143718B1 (de)
CN (1)	CN1946714B (de)
AR (1)	AR047890A1 (de)
AT (3)	ATE542816T1 (de)
AU (2)	AU2005215918C1 (de)
BR (1)	BRPI0507945A (de)
CA (1)	CA2557115C (de)
CY (3)	CY1109854T1 (de)
DE (1)	DE602005018190D1 (de)
DK (3)	DK2060570T3 (de)
ES (2)	ES2380990T3 (de)
HK (1)	HK1103016A1 (de)
HR (3)	HRP20100114T1 (de)
IL (1)	IL177184A0 (de)
MA (1)	MA28438B1 (de)
NO (1)	NO20064309L (de)
PE (1)	PE20051173A1 (de)
PL (3)	PL2060570T3 (de)
PT (3)	PT2060570E (de)
RU (1)	RU2434011C2 (de)
SI (3)	SI2060570T1 (de)
TW (1)	TW200538113A (de)
WO (1)	WO2005080382A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4960217B2 (ja) *	2004-02-23	2012-06-27	グラクソグループリミテッド	ドーパミンｄ３受容体のモジュレーターとして有用なアザビシクロ（３．１．０）ヘキサン誘導体
US20070043100A1 (en)	2005-08-16	2007-02-22	Hagen Eric J	Novel polymorphs of azabicyclohexane
GB0507601D0 (en) *	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507602D0 (en)	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507680D0 (en) *	2005-04-15	2005-05-25	Glaxo Group Ltd	Compounds
GB0512099D0 (en)	2005-06-14	2005-07-20	Glaxo Group Ltd	Compounds
US7807698B2 (en) *	2005-06-14	2010-10-05	Glaxo Group Limited	Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor
WO2007006117A1 (en) *	2005-07-13	2007-01-18	Nicogen Inc.	Novel cyp2a6 inhibitors
CA2659215C (en)	2005-07-27	2018-07-10	Dov Pharmaceutical, Inc.	Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
GB0517187D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517175D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517193D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Novel use
WO2007022933A1 (en) *	2005-08-22	2007-03-01	Glaxo Group Limited	Triazole derivatives as modulators of dopamine d3 receptors
GB0517191D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
KR20080109063A (ko)	2006-04-03	2008-12-16	글락소 그룹 리미티드	도파민 ｄ3 수용체 조절제로서의 아자비시클로[3.1.0]헥실 유도체
WO2007113258A1 (en) *	2006-04-03	2007-10-11	Glaxo Group Limited	Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors
GB0703387D0 (en) *	2007-02-21	2007-03-28	Glaxo Group Ltd	Novel compounds
EP2007751B1 (de) *	2006-04-03	2013-08-21	Glaxo Group Limited	Azabicyclo[3.1.0]hexylderivate als modulatoren von dopamin-d3-rezeptoren
GB0607899D0 (en)	2006-04-03	2006-05-31	Glaxo Group Ltd	Process for preparing heterocyclic derivatives
GB0608452D0 (en) *	2006-04-27	2006-06-07	Glaxo Group Ltd	Novel compounds
US20080045725A1 (en)	2006-04-28	2008-02-21	Murry Jerry A	Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
GB0616574D0 (en) *	2006-08-21	2006-09-27	Glaxo Group Ltd	Compounds
US8138377B2 (en)	2006-11-07	2012-03-20	Dov Pharmaceutical, Inc.	Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US20090069374A1 (en) *	2007-06-06	2009-03-12	Phil Skolnick	Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US9133159B2 (en)	2007-06-06	2015-09-15	Neurovance, Inc.	1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0719234D0 (en) *	2007-10-02	2007-11-14	Glaxo Group Ltd	Novel compounds
GB0719235D0 (en)	2007-10-02	2007-11-14	Glaxo Group Ltd	Novel compounds
JP2011525533A (ja)	2008-06-24	2011-09-22	コデクシス，インコーポレイテッド	実質的に立体異性的に純粋な縮合二環式プロリン化合物の調製のための生体触媒法
BRPI0919004A2 (pt)	2008-09-22	2019-09-24	Cayman Chem Co	composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2
EP2445887B1 (de) *	2009-06-26	2014-11-05	Panacea Biotec Limited	Neuartige azabicyclohexane
US20140206740A1 (en)	2011-07-30	2014-07-24	Neurovance, Inc.	Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
WO2015070253A1 (en) *	2013-11-11	2015-05-14	Euthymics Bioscience, Inc.	Novel methods
CA2992820C (en)	2015-08-05	2022-08-16	Indivior Uk Limited	Dopamine d3 receptor antagonists having a bicyclo moiety
WO2019146740A1 (ja)	2018-01-26	2019-08-01	塩野義製薬株式会社	ドーパミンｄ３受容体拮抗作用を有する環式化合物
CN116113627A (zh)	2020-06-22	2023-05-12	科赛普特治疗公司	季吲哚糖皮质激素受体拮抗剂
US12115154B2 (en)	2020-12-16	2024-10-15	Srx Cardio, Llc	Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
EP4452968A1 (de) *	2021-12-21	2024-10-30	Corcept Therapeutics Incorporated	Bicyclische indazol-glucocorticoid-rezeptorantagonisten
TWI835476B (zh)	2021-12-21	2024-03-11	美商科賽普特治療學股份有限公司	哌嗪吲唑糖皮質素受體拮抗劑

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI274750B (en) *	1999-01-12	2007-03-01	Abbott Gmbh & Co Kg	Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
GB0015562D0 (en)	2000-06-23	2000-08-16	Pfizer Ltd	Heterocycles
PL362992A1 (en) *	2000-11-14	2004-11-15	Smithkline Beecham P.L.C.	Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
US6569887B2 (en) *	2001-08-24	2003-05-27	Dov Pharmaceuticals Inc.	(−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
EP1440059B1 (de) *	2001-10-22	2008-04-16	Pfizer Products Inc.	3-azabicyclo(3.1.0)hexan derivative als antagonisten der opioid rezeptoren
CN101723941A (zh) *	2002-08-09	2010-06-09	阿斯利康(瑞典)有限公司	作为代谢型谷氨酸受体-5调节剂的“1,2,4”二唑
JP4960217B2 (ja) *	2004-02-23	2012-06-27	グラクソグループリミテッド	ドーパミンｄ３受容体のモジュレーターとして有用なアザビシクロ（３．１．０）ヘキサン誘導体
GB0507602D0 (en)	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507601D0 (en) *	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507680D0 (en) *	2005-04-15	2005-05-25	Glaxo Group Ltd	Compounds
US7807698B2 (en)	2005-06-14	2010-10-05	Glaxo Group Limited	Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor
GB0517175D0 (en)	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517187D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517193D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Novel use
GB0517191D0 (en)	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
WO2007022933A1 (en) *	2005-08-22	2007-03-01	Glaxo Group Limited	Triazole derivatives as modulators of dopamine d3 receptors
KR20080109063A (ko)	2006-04-03	2008-12-16	글락소 그룹 리미티드	도파민 ｄ3 수용체 조절제로서의 아자비시클로[3.1.0]헥실 유도체
GB0616574D0 (en) *	2006-08-21	2006-09-27	Glaxo Group Ltd	Compounds

2005
- 2005-02-21 JP JP2007500152A patent/JP4960217B2/ja not_active Expired - Fee Related
- 2005-02-21 PT PT08169935T patent/PT2060570E/pt unknown
- 2005-02-21 AT AT08169935T patent/ATE542816T1/de active
- 2005-02-21 SI SI200531503T patent/SI2060570T1/sl unknown
- 2005-02-21 US US10/598,200 patent/US7855298B2/en not_active Expired - Fee Related
- 2005-02-21 EP EP08169935A patent/EP2060570B1/de active Active
- 2005-02-21 PT PT05707610T patent/PT1745040E/pt unknown
- 2005-02-21 CN CN2005800126155A patent/CN1946714B/zh not_active Expired - Fee Related
- 2005-02-21 BR BRPI0507945-4A patent/BRPI0507945A/pt active Search and Examination
- 2005-02-21 DK DK08169935.7T patent/DK2060570T3/da active
- 2005-02-21 ES ES08169935T patent/ES2380990T3/es active Active
- 2005-02-21 PL PL08169935T patent/PL2060570T3/pl unknown
- 2005-02-21 AR ARP050100632A patent/AR047890A1/es not_active Application Discontinuation
- 2005-02-21 KR KR1020067016833A patent/KR101143718B1/ko not_active IP Right Cessation
- 2005-02-21 PE PE2005000205A patent/PE20051173A1/es not_active Application Discontinuation
- 2005-02-21 AU AU2005215918A patent/AU2005215918C1/en not_active Ceased
- 2005-02-21 AT AT05707610T patent/ATE451364T1/de active
- 2005-02-21 PL PL05707610T patent/PL1745040T3/pl unknown
- 2005-02-21 SI SI200530923T patent/SI1745040T1/sl unknown
- 2005-02-21 RU RU2006133909/04A patent/RU2434011C2/ru not_active IP Right Cessation
- 2005-02-21 EP EP05707610A patent/EP1745040B9/de active Active
- 2005-02-21 DK DK05707610.1T patent/DK1745040T3/da active
- 2005-02-21 WO PCT/EP2005/001940 patent/WO2005080382A1/en active Application Filing
- 2005-02-21 CA CA2557115A patent/CA2557115C/en not_active Expired - Fee Related
- 2005-02-21 ES ES05707610T patent/ES2337590T3/es active Active
- 2005-02-21 PT PT08169934T patent/PT2070922E/pt unknown
- 2005-02-21 SI SI200531398T patent/SI2070922T1/sl unknown
- 2005-02-21 AT AT08169934T patent/ATE520686T1/de active
- 2005-02-21 DK DK08169934.0T patent/DK2070922T3/da active
- 2005-02-21 PL PL08169934T patent/PL2070922T3/pl unknown
- 2005-02-21 DE DE602005018190T patent/DE602005018190D1/de active Active
- 2005-02-21 EP EP08169934A patent/EP2070922B1/de active Active
- 2005-02-21 TW TW094105108A patent/TW200538113A/zh unknown
2006
- 2006-07-31 IL IL177184A patent/IL177184A0/en unknown
- 2006-08-22 MA MA29286A patent/MA28438B1/fr unknown
- 2006-09-22 NO NO20064309A patent/NO20064309L/no not_active Application Discontinuation
2007
- 2007-07-12 HK HK07107486.9A patent/HK1103016A1/xx not_active IP Right Cessation
2009
- 2009-09-01 AU AU2009212887A patent/AU2009212887A1/en not_active Abandoned
- 2009-12-16 US US12/639,282 patent/US8283474B2/en not_active Expired - Fee Related
- 2009-12-16 US US12/639,129 patent/US8263782B2/en not_active Expired - Fee Related
2010
- 2010-03-01 CY CY20101100197T patent/CY1109854T1/el unknown
- 2010-03-02 HR HR20100114T patent/HRP20100114T1/hr unknown
2011
- 2011-10-26 HR HR20110781T patent/HRP20110781T1/hr unknown
- 2011-11-07 CY CY20111101073T patent/CY1112011T1/el unknown
2012
- 2012-03-29 HR HR20120281T patent/HRP20120281T1/hr unknown
- 2012-04-11 CY CY20121100356T patent/CY1113029T1/el unknown

Also Published As

Publication number	Publication date
EP2070922B1 (de)	2011-08-17
CN1946714B (zh)	2011-06-15
RU2434011C2 (ru)	2011-11-20
HRP20120281T1 (hr)	2012-04-30
AU2009212887A1 (en)	2009-09-24
KR20060127991A (ko)	2006-12-13
PT2060570E (pt)	2012-05-07
CY1109854T1 (el)	2014-09-10
ATE542816T1 (de)	2012-02-15
ES2380990T3 (es)	2012-05-22
CA2557115A1 (en)	2005-09-01
TW200538113A (en)	2005-12-01
EP1745040B9 (de)	2010-06-02
NO20064309L (no)	2006-11-23
US7855298B2 (en)	2010-12-21
CY1112011T1 (el)	2015-11-04
AU2005215918B2 (en)	2009-06-11
PL2060570T3 (pl)	2012-06-29
JP2007523208A (ja)	2007-08-16
EP2060570A2 (de)	2009-05-20
KR101143718B1 (ko)	2012-07-05
CA2557115C (en)	2012-10-02
PL2070922T3 (pl)	2012-01-31
CN1946714A (zh)	2007-04-11
CY1113029T1 (el)	2016-04-13
US20100152195A1 (en)	2010-06-17
HRP20110781T1 (hr)	2011-11-30
PT1745040E (pt)	2010-03-08
DK2060570T3 (da)	2012-04-30
WO2005080382A1 (en)	2005-09-01
RU2006133909A (ru)	2008-03-27
SI2060570T1 (sl)	2012-05-31
SI2070922T1 (sl)	2011-12-30
SI1745040T1 (sl)	2010-04-30
PT2070922E (pt)	2011-11-24
US20100160336A1 (en)	2010-06-24
BRPI0507945A (pt)	2007-07-24
HRP20100114T1 (hr)	2010-04-30
DK2070922T3 (da)	2011-11-28
EP2070922A1 (de)	2009-06-17
US20070142438A1 (en)	2007-06-21
US8283474B2 (en)	2012-10-09
HK1103016A1 (en)	2007-12-14
AU2005215918C1 (en)	2010-01-21
EP1745040A1 (de)	2007-01-24
AR047890A1 (es)	2006-03-01
MA28438B1 (fr)	2007-02-01
ATE520686T1 (de)	2011-09-15
ES2337590T3 (es)	2010-04-27
EP2060570A3 (de)	2009-06-03
DE602005018190D1 (de)	2010-01-21
IL177184A0 (en)	2006-12-10
AU2005215918A1 (en)	2005-09-01
PL1745040T3 (pl)	2010-05-31
PE20051173A1 (es)	2006-02-14
EP1745040B1 (de)	2009-12-09
US8263782B2 (en)	2012-09-11
DK1745040T3 (da)	2010-04-12
EP2060570B1 (de)	2012-01-25
JP4960217B2 (ja)	2012-06-27

Publication	Publication Date	Title
ATE451364T1 (de)	2009-12-15	Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
DE602005027307D1 (de)	2011-05-19	Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
CY2017008I2 (el)	2017-11-14	Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
ATE421511T1 (de)	2009-02-15	Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE497953T1 (de)	2011-02-15	Thiazolderivate als modulatoren des cannabinoidrezeptors
ATE439357T1 (de)	2009-08-15	Indolylderivate als liver-x-rezeptormodulatoren
ATE509928T1 (de)	2011-06-15	8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
ATE481383T1 (de)	2010-10-15	3-aza-bicycloä3.1.0ühexanderivate
ATE495167T1 (de)	2011-01-15	Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
FR2895868B1 (fr)	2010-04-09	Dispositif de casque d'ecoute
ATE487691T1 (de)	2010-11-15	Acetylenderivate
NL2000241A1 (nl)	2007-03-22	Carboxamidederivaten als muscarine-receptorantagonisten.
ATE429428T1 (de)	2009-05-15	Indanderivate als antagonisten des mch-rezeptors
DK1899324T3 (da)	2012-02-13	Benzimidazolcarboxamid-forbindelser som 5-HT4-receptoragonister
ATE518834T1 (de)	2011-08-15	2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
ATE496049T1 (de)	2011-02-15	Als monoamin wiederaufnahmehemmer geeignete 8- azabicycloä3.2.1üoctanderivate
DE602004014772D1 (de)	2008-08-14	Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
DE602006015186D1 (de)	2010-08-12	Oxindole als kinaseinhibitoren
ATE488519T1 (de)	2010-12-15	Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
ATE469900T1 (de)	2010-06-15	Spiropiperidinderivate als antagonisten des via- rezeptors
ES1065052Y (es)	2007-09-16	Dispositivo para el suministro de perfume
DE112005002826A5 (de)	2007-12-27	Ausgleichseinheit
ATE538121T1 (de)	2012-01-15	1,5,6-substituierte-2-oxo-3-cyano-1,6a- diazatetrahydrofluoranthene als antiinfektionsmittel
FI20040569A0 (fi)	2004-04-23	Tuloilmalaite
DE602006010432D1 (de)	2009-12-24	Carbamatverbindungen als agonisten am 5-ht4-rezeptor

Legal Events

Date	Code	Title	Description
2010-06-15	UEP	Publication of translation of european patent specification	Ref document number: 1745040 Country of ref document: EP

Date

Code

Title

Description

2010-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1745040

Country of ref document: EP